BIO Comments on FDA Draft Guidance on Patient-Focused Drug Development: Collecting Comprehensive and Representative Input
September 11, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Patient-Focused Drug Development: Collecting Comprehensive and Representative Input.
In the comments, BIO applauds the FDA’s initiative to advance the use of patient-experience data (PED) to inform drug development and regulatory review. BIO sees this first draft guidance, addressing comprehensive and representative input, as an important tool for strengthening our collective understanding of the evidence needed to support the FDA regulatory process with PED.
BIO says the guidance presents standards that adhere to established standards for good research practice and provides enough information to gain insight into what is needed to compose an appropriate research study, but BIO strongly believes future guidance documents should emphasize the FDA’s willingness to exercise regulatory flexibility and acceptance of innovative designs and approaches for collecting PED. BIO’s comments provide suggestions for changes to the guidance to encourage broader adoption of PED.
Download Full Comments Below
BIO Letter Collecting Comprehensive And Representative Input FDA 2018-D-1893
Dear Colleagues,This month marks my one-year anniversary as BIO’s CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request forComments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Patient-Focused Drug Development: Collecting Comprehensive and Representative Input.
In the comments, BIO applauds the FDA’s initiative to advance the use of patient-experience data (PED) to inform drug development and regulatory review. BIO sees this first draft guidance, addressing comprehensive and representative input, as an important tool for strengthening our collective understanding of the evidence needed to support the FDA regulatory process with PED.
BIO says the guidance presents standards that adhere to established standards for good research practice and provides enough information to gain insight into what is needed to compose an appropriate research study, but BIO strongly believes future guidance documents should emphasize the FDA’s willingness to exercise regulatory flexibility and acceptance of innovative designs and approaches for collecting PED. BIO’s comments provide suggestions for changes to the guidance to encourage broader adoption of PED.